OJOph  Vol.4 No.2 , May 2014
Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost
Abstract: Objectives: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of bimatoprost 0.03%/timolol 0.50%, timolol 0.50% or bimatoprost 0.01% eye drops. Methods: This is a prospective, one center, open-label clinical trial. It was performed on 60 glaucoma patients between 01-01-2012 and 12-31-2012. These patients were randomly divided in three subgroups: bimatoprost 0.03%/timolol 0.50% fixed combination, timolol 0.50% and bimatoprost 0.01%. The Ocular Surface Disease Index (O.S.D.I.) was evaluated in all the glaucomatous patients of the three subgroups at basal time and after 6 and 12 months. All the results were statistically evaluated by Student t-test and one-way ANOVA. The results were considered statistically significant if p < 0.05. Results: All of the patients ended the clinical trial. There was no statistical significant difference between patients treated with the bimatoprost 0.03%/timolol 0.50% fixed combination and timolol 0.50% eye drops alone (p = 0.845). Instead, there was a statistically significant difference between bimatoprost 0.01% and bimatoprost 0.03%/timolol 0.50% patients (p = 0.05) and between bimatoprost 0.01% and timolol 0.50% eye drops alone (p = 0.049). Conclusions: This is a clinical trial based not on the hypotonising effect of these drugs but on their tolerability. The drug which showed the best tolerability is bimatoprost 0.01%.
Cite this paper: Giuffrè, I. (2014) Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost. Open Journal of Ophthalmology, 4, 36-39. doi: 10.4236/ojoph.2014.42007.

[1]   Russ, H.H., Nogueira-Filho, P.A., Barros Jde, N., et al. (2013) Ocular Surface Evaluation in Patients Treated with a Fixed Combination of Prostaglandin Analogues with 0.5% Timolol Maleate Topical Monotherapy: A Randomized Clinical Trial. Clinics (Sao Paulo), 68, 1318-1324.

[2]   Nixon, D.R. (2013) A Randomized, Prospective Study of Bimatoprost 0.01% or Travoprost/Timolol in Patients Previously Treated with Latanoprost and Timolol to Reduce Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics, 29, 876-881.

[3]   Pfennigsdorf, S., de Jong, L., Makk, S., et al. (2013) A Combined Analysis of Five Observational Studies Evaluating the Efficacy and Tolerability of Bimatoprost/Timolol Fixed Combination in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Journal of Clinical Ophthalmology, 7, 1219-1225.

[4]   Shafiee, A., Bowman, L.M., Hou, E., et al. (2013) Ocular Pharmacokinetics of Bimatoprost Formulated in DuraSite Compared to Bimatoprost 0.03% Ophthalmic Solution in Pigmented Rabbit Eyes. Journal of Clinical Ophthalmology, 7, 1549-1556.

[5]   Campbell, J.H., Schwartz, G., Labounty, B., et al. (2013) Comparison of Adherence and Persistence with Bimatoprost 0.01% versus Bimatoprost 0.03% Topical Ophthalmic Solutions. Current Medical Research and Opinion, 29, 1201-1209.

[6]   Wong, W.B., Patel, V.D., Kowalski, J.W., et al. (2013) An Adherence Based Cost-Consequence Model Comparing Bimatoprost 0.01% to Bimatoprost 0.03%. Current Medical Research and Opinion, 29, 1191-1200.

[7]   Alany, R.G. (2013) Adherence, Persistence and Cost-Consequence Comparison of Bimatoprost Topical Ocular Formulations. Current Medical Research and Opinion, 29, 1187-1189.

[8]   Stewart, W.C., Kolker, A.E., Stewart, J.A., et al. (2003) Conjunctival Hyperemia in Healthy Subjects after Short-Term Dosing with Latanoprost, Bimatoprost, and Travoprost. American Journal of Ophthalmology, 135, 314-320.

[9]   Johnstone, M.A. (1997) Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost. American Journal of Ophthalmology, 124, 544-547.

[10]   Kook, M.S. and Lee, K. (2000) Increased Eyelid Pigmentation Associated with the Use of Latanoprost. American Journal of Ophthalmology, 129, 804-806.

[11]   Herreras, J.M., Pastor, J.C., Calonge, M., et al. (1992) Ocular Surface Alteration after Long-Term Treatment with Antiglaucomatous Drug. Ophthalmology, 99, 1082-1088.

[12]   Nuzzi, R., Finazzo, C. and Cerruti, A. (1998) Adverse Effects of Topical Antiglaucomatous Medications on the Conjunctiva and the Lacrymal. International Ophthalmology, 22, 31-35.

[13]   Broadway, D.C., Grierson, I., O’Brien, C., et al. (1994) Adverse Effects of Topical Antiglaucoma Medication. The Conjunctival Cell Profile. Archives of Ophthalmology, 112, 1437-1445.

[14]   Arici, M.K., Arici, D.S., Topalkara, A., et al. (2000) Adverse Effects of Topical Antiglaucoma Drugs on the Ocular Surface. Journal of Clinical & Experimental Ophthalmology, 28, 113-117.